| Literature DB >> 21375716 |
Mary O'Connell Motherway1, Gerald F Fitzgerald, Douwe van Sinderen.
Abstract
In this study, we describe the functional characterization of the Bifidobacterium breve UCC2003 gal locus, which is dedicated to the utilization of galactan, a plant-derived polysaccharide. Using a combination of molecular approaches we conclude that the galA gene of B. breve UCC2003 encodes a β-1,4-endogalactanase producing galacto-oligosaccharides, which are specifically internalized by an ABC transport system, encoded by galBCDE, and which are then hydrolysed to galactose moieties by a dedicated intracellular β-galactosidase, specified by galG. The generated galactose molecules are presumed to be fed into the fructose-6-phosphate phosphoketolase pathway via the Leloir pathway, thereby allowing B. breve UCC2003 to use galactan as its sole carbon and energy source. In addition to these findings we demonstrate that GalR is a LacI-type DNA-binding protein, which not only appears to control transcription of the galCDEGR operon, but also that of the galA gene.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21375716 PMCID: PMC3818998 DOI: 10.1111/j.1751-7915.2010.00218.x
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Figure 1Final optical density (OD600) values obtained following 24 h growth of various bifidobacterial strains in modified MRS containing 0.5% glucose, potato galactan, potato‐derived pectic arabinogalactan or arabinogalactan derived from larch wood as the sole carbon source. The results are mean values obtained from three separate experiments.
Effect of potato galactan on the transcriptome of B. breve UCC2003.
| Locus tag_gene | Putative function | Galactan | QRT‐PCR |
|---|---|---|---|
| bbr_0417_ | Solute binding protein | ||
| bbr_0418_ | Sugar permease protein | ||
| bbr_0419_ | Sugar permease protein | ||
| bbr_0420_ | β‐galactosidase GH 42 family | ||
| bbr_0421_ | Transcriptional regulator, LacI family | 6.6 | 3.0 |
| bbr_0422_ | Endogalactanase |
Expression ratios presented in bold have a Bayesian P‐value < 0.001 according to the Cyber‐T‐test (Long ).
Expression ratios of selected genes quantified by QRT‐PCR. cDNA templates were derived from RNA samples of B. breve UCC2003 culture grown on ribose as a comparator.
Figure 2Comparison of the gal locus of B. breve UCC2003 with corresponding putative galacto‐oligosaccharides/galactan utilization loci from other bifidobacteria. Each solid arrow indicates an open reading frame. The lengths of the arrows are proportional to the length of the predicted open reading frame and the gene locus name, which is indicative of its putative function, is indicated within the arrow. Orthologs are marked with the same colour while the amino acid identity of each predicted protein is indicated as a percentage relative to its equivalent protein encoded by B. breve UCC2003. The bent arrows indicate the galc and galA promoters; the lollipop sign designates putative rho‐independent terminator region.
Figure 3Substrate specificity of GalA, GalAT or GalG as determined by HPTLC. Lane 3–6 contain hydrolysis products of potato galactan following incubation with GalA (lane 3), GalA plus GalG (lane 4), GalAT (lane 5), GalAT plus GalG (lane 6). The hydrolysis products of galactobiose and lactose following incubation with GalG are in lanes 8 and 9 respectively. Carbohydrate standards (lanes 1 and 10) are listed to the left and right of the panel, while lanes 2 and 7 contain potato galactan and galactobiose respectively.
Bacterial strains and plasmids used in this study.
| Strains and plasmids | Relevant features | Reference or source |
|---|---|---|
| Strains | ||
| | ||
| | Cloning host, repA+ kmr | |
| | EC101 harbouring pNZ8048 derivative containing | |
| | ||
| | MG1363, | |
| | NZ9000 containing pNZ‐galA | This study |
| | NZ9000 containing pNZ‐galAT | This study |
| | NZ9000 containing pNZ‐galG | This study |
| | NZ9000 containing pNZ‐galR | This study |
| | ||
| | Isolate from nursling stool | |
| | pORI19‐tet‐galA‐967 insertion mutant of UCC2003 | This study |
| | pORI19‐tet‐galG‐410 insertion mutant of UCC2003 | This study |
| | pORI19‐tet‐galC‐701 insertion mutant of UCC2003 | This study |
| | Isolate from human faeces | UCC |
| | Isolate from human faeces | UCC |
| | Isolate from human faeces | UCC |
| | Isolate from human faeces | JCM |
| | Isolate from infant faeces | JCM |
| | Isolate from infant intestine | NCFB |
| | Isolate from infant intestine | NCFB |
| | Isolate from infant intestine | NCTC |
| | Isolate from human faeces | CCUG |
| | Isolate from human intestine | CIP |
| | Isolate from human intestine | DSM |
| | Isolate from human intestine | NCFB |
| | Isolate from human intestine | NCFB |
| | Isolate from human intestine | LMG |
| | Isolate from calf faeces | JCM |
| | Isolate from chicken faeces | DSM |
| | Isolate from human intestine | NCIMB |
| | Isolate from animal intestine | LMG |
| | Isolate from human dental caries | |
| | Isolate from human dental caries | ATCC |
| | Isolate from human faeces | JCM |
| | Isolate from human faeces | JCM |
| | Isolate from infant faeces | JCM |
| | Isolate from infant faeces | JCM |
| | Isolate from infant intestine | CIP |
| | Isolate from human abdomen | CCUG |
| | Isolate from human faeces | NCIMB |
| | Isolate from human | CCUG |
| | Isolate from human faeces | CCUG |
| | Isolate from human faeces | CCUG |
| | Isolate from human faeces | ATCC |
| | Isolate from infant intestine | NCDO |
| | Isolate from infant faeces | LMG |
| | Isolate from infant faeces | NCIMB |
| | Isolate from swine faeces | NCIMB |
| | Isolate from chicken faeces | DSM |
| | Isolate from animal rumen | JCM |
| | Isolate from bovine rumen | JCM |
| Isolate from swine faeces | JCM | |
| Plasmids | ||
| pNZ8150 | Cmr, nisin‐inducible translational fusion vector | |
| pNZ‐galA | Cmr, pNZ8150 derivative containing translational fusion of | This study |
| pNZ‐galAT | Cmr, pNZ8150 derivative containing translational fusion of truncated | This study |
| pNZ‐galG | Cmr, pNZ8150 derivative containing translational fusion of | This study |
| pNZ‐galR | Cmr, pNZ8150 derivative containing translational fusion of | This study |
| pNZ44 | pNZ8048 containing constitutive p44 promoter from Lactococcal chromosome | |
| pSKEM | ||
| pCIB‐p44 | Complementation vector; pNZ44 where repA has been replaced with pCIBA089 rep | This study |
| pCIB‐p44‐galG | pCIB‐p44 derivative with | This study |
| pAM5 | pBC1‐puC19‐Tcr | |
| pORI19 | Emr, repA‐, ori+, cloning vector | |
| pORI19‐tet‐galA | Internal 967 bp fragment of | This study |
| pORI19‐tet‐galG | Internal 410 bp fragment of | This study |
| pORI19‐tet‐galC | Internal 701 bp fragment of | This study |
ATCC, American type culture collection; CCUG, Culture Collection of the University of Goteborg; CIP, Collection de l'Institut Pasteur; DSM, German Collection of Microorganisms and Cell Cultures; JCM, Japan Collection of Microorganisms; LMG, Belgian Co‐ordinated Collection of Microorganisms; NCDO, National Collection of Dairy Organisms; NCFB, National Collection of Food Bacteria; NCIMB, National Collection of Industrial and Marine Bacteria; NCTC, National Collection of Type Cultures; UCC, University College Cork Culture Collection.
Figure 4Growth profile analysis of B. breve UCC2003, UCC2003‐galC, UCC2003‐galG and mutant strains harbouring pCIB‐p44 (control) or pCIB‐p44‐galG in modified rogosa broth supplemented with potato galactan or glucose.
Figure 5Schematic representation of the B. breve UCC2003 galA (panel A I) and galC (panel B I) promoter regions. Boldface type and underlining indicate the −10 and −35 hexamers as deduced from the primer extension results (Panel A II‐galA and B II‐galC) and ribosomal binding site (RBS); the transcriptional start sites (TSS) are indicated by asterisks; arrows under sequence in bold indicate the inverted repeat sequence that represents the GalR binding sequence. The inverted repeat sequences galAIR1 and IR2 and galCIR1 and IR2 are indicated as broken thick black line underneath the respective sequences.
Figure 6Panel A: Representation of the B. breve UCC2003 endogalactanase operon and DNA fragments used in electrophoretic mobility shift assays (EMSAs) for the galC and galA promoter resions. Plus and minus signs indicate whether or not GalR was able to bind to the particular DNA fragment respectively. Panel B: EMSA showing GalR interaction with DNA fragments encompassing fragment g1 and sbp1. Panel C: Alignment and web logo representation of predicted binding sequences of GalR together with EMSAs illustrating GalR interaction with galCIR1, galCIR2 and mutated derivatives mu‐galCIR1 and mu‐galCIR2. In each panel lane X represents a binding reaction to which no protein was added, while the remaining lanes represent binding reactions with the respective DNA probes incubated with increasing amounts of GalR (concentrations ranging from 0.04 nM 0.01 µM). Each successive lane, from right to left, corresponds to a doubling in the concentration of GalR. Panel D: EMSA showing GalR interaction with the DNA fragment g1 with the addition of galactobiose at concentrations ranging from 20–2 µM.